Alnylam and Tenaya agree cardiovascular disease collab
Alnylam Pharmaceuticals and Tenaya Therapeutics have agreed a research collaboration to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases. Under the terms of the agreement, Tenaya Therapeutics will validate up to 15 gene targets. In return, Tenaya will… Read More